Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. (NVCT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NVCT · as of Sep 30, 2025
Ownership Breakdown
55
Institutional Holders
▲ 6 vs Q2
$22.24M
Total Inst. Value
▼ $1.97M vs Q2
26.53M
Shares Outstanding
freeFloat 58.34%
3.69M
13F Shares Held
▲ 452,154 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NVCT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 698.7K | 3.27% | 3.27% | $4.21B | Nov 7, 2025 | ▲ 31.9K |
BLACKROCK, INC. pharmaceutical preparations | 685.3K | 3.21% | 3.21% | $4.13B | Nov 12, 2025 | ▲ 42.4K |
IRIDIAN ASSET MANAGEMENT LLC/CT pharmaceutical preparations | 405.6K | 1.90% | 1.90% | $2.44B | Oct 24, 2025 | ▲ 32.9K |
BALDWIN BROTHERS LLC/MA pharmaceutical preparations | 350.5K | 1.64% | 1.64% | $2.11B | Oct 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 325.7K | 1.52% | 1.52% | $1.96B | Nov 12, 2025 | ▲ 40.4K |
pharmaceutical preparations | 290.0K | 1.36% | 1.36% | $1.75B | Nov 14, 2025 | NEW |
STATE STREET CORP pharmaceutical preparations | 136.7K | 63.99% | 63.99% | $823.03M | Nov 14, 2025 | ▲ 23.1K |
NORTHERN TRUST CORP pharmaceutical preparations | 106.6K | 49.91% | 49.91% | $641.98M | Nov 14, 2025 | ▼ 3.2K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 90.9K | 42.53% | 42.53% | $547.09M | Nov 14, 2025 | ▲ 45.6K |
CITADEL ADVISORS LLC pharmaceutical preparations | 87.3K | 40.86% | 40.86% | $525.55M | Nov 14, 2025 | ▲ 64.6K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
15
Increased
+371.6K shares6
New Positions
first time holders16
Decreased
−123.0K shares0
Sold Out
fully exitedNet shares change (top 50)
+248.6K
+371.6K / −123.0K
Net new holders
+5
6 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NVCT insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Shemesh Shay Chief Dev. & Ops. Officer | Jan 6, 2026 | Award | 150,000 | — | — | 1.79M | Form 4 ↗ |
BENTSUR RON Chairman & CEO | Jan 6, 2026 | Award | 150,000 | — | — | 3.68M | Form 4 ↗ |
Poradosu Enrique Chief Science & Business Off | Jan 6, 2026 | Award | 150,000 | — | — | 1.81M | Form 4 ↗ |
Carson Michael J. Vice President, Finance | Jan 6, 2026 | Award | 61,200 | — | — | 200.1K | Form 4 ↗ |
BENTSUR RON Chairman & CEO | Nov 5, 2025 | Purchase | 5,000 | $5.72 | $28.6K | 3.53M | Form 4 ↗ |
Sanchez Juan director | Nov 5, 2025 | Purchase | 13,000 | $5.79 | $75.3K | 78.2K | Form 4 ↗ |
Kaplan Matthew L. director | Nov 5, 2025 | Purchase | 11,000 | $5.84 | $64.2K | 124.8K | Form 4 ↗ |
Sanchez Juan director | Sep 22, 2025 | Award | 30,000 | — | — | 65.2K | Form 4 ↗ |
Mosseri Marlio Charles 10 percent owner | Oct 27, 2025 | Purchase | 72,836 | $6.28 | $457.4K | 3.14M | Form 4 ↗ |
Mosseri Marlio Charles 10 percent owner | Oct 24, 2025 | Purchase | 35,034 | $6.15 | $215.5K | 3.06M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Nuvectis Pharma, Inc. (NVCT) is primarily owned by institutional investors, who hold approximately 13.9% of total shares outstanding. Company insiders own approximately 41.66%, while retail and public investors account for the remaining 44.41%.
The largest institutional shareholder of Nuvectis Pharma, Inc. is VANGUARD GROUP INC, holding approximately 698,708 shares — equal to 3.27% of outstanding shares — as of September 30, 2025.
A total of 55 institutional investors currently hold NVCT stock, with a combined institutional value of approximately $22,241,038 as of the most recent 13F filing period.
Frequently asked questions
NVCT ownershipNuvectis Pharma, Inc. (NVCT) is primarily owned by institutional investors, who hold approximately 13.9% of shares. The largest shareholder is VANGUARD GROUP INC with a 3.27% stake. Company insiders hold 41.66%. Data sourced from SEC Form 13F as of September 30, 2025.